DEVELOPMENT AND VALIDATION OF UV SPECTROSCOPIC METHODS FOR SIMULTANEOUS ESTIMATION OF SALBUTAMOL SULPHATE AND DOXOPHYLLINE IN COMBINED SOLID DOSAGE FORM

Objective: Salbutamol sulphate (SBS) and doxophylline (DOX) was used for the treatment of asthma and bronchitis. In the present study, two simple, accurate, precise, reproducible and economical UV-spectroscopic methods (A and B) for simultaneous estimation of SBS and DOX in tablet dosage form have been developed.Methods: In the present study the simultaneous estimation of SBS and DOX was carried out by two methods. Method A employs solving of simultaneous equations based on the measurement of absorbance at two wavelengths, 272 nm and 276 nm which are the ðœ†max values of SBS and DOX respectively in phosphate buffer (pH 7.4). Method B is based on the principle of Q-Analysis where in, absorbance was measured at 225 nm (iso-absorptive point, ðœ†1) and 276 nm (ðœ†max of DOX, ðœ†2) in phosphate buffer (pH 7.4).Results: Both SBS and DOX shows linearity at all the selected wavelengths and obeys beer's law in the concentration range of between 0.2-1.6ðœ‡g/ml and 0.1-3.5μg/ml at 276 nm; 0.2-1.6 µg/ml and 0.1-4.5 µg/ml at 272 nm and 0.2-2.0µg/ml and 0.2-3.5μg/ml at iso-absorptive point 225 nm. Recovery studies for SBS and DOX were performed and the percentage recovery for both the drugs was obtained in the range of 97.45-98.63% (Method A) and 97.49–98.87 % (Method B) confirming the accuracy of the proposed method.Conclusion: Both the methods showed good reproducibility and recovery with % RSD less than 2. Statistical validation of the data shows that the proposed methods can be successfully applied for the routine analysis of drugs in commercial tablets. Hence, it could be used in the analysis of laboratory samples and marketed formulations containing these two drugs in combined dosage form without the interference of common excipients

Short review on domperidone tablet

Oral route is presently the gold standard in the pharmaceutical industry where it is regarded as the safest, most economical and most convenient method of drug delivery resulting in highest patient compliance. Pediatric and geriatric patients find it difficult to swallow solid dosage forms like tablets. Mouth dissolving tablet that dissolve or disintegrate rapidly in oral cavity result in solution, is an ultimate remedy for this problem in addition they give pleasing mouth feeling. ODT has advantages such as patient compliance, quick onset of action, improved bioavailability. Domperidone tablet (ODT) gives relief from nausea, vomiting. This review gives us all information about pharmacokinetic, pharmacodynamic, uses, precautions, side effects of domperidone tablet

FORMULATION AND IN-VITRO EVALUATION OF TRANSDERMAL MATRIX PATCHES OF DOXOPHYLLINE.

Objective: The objective of the present study was to fabricate matrix type transdermal patch with varied proportion of hydrophilic (HPMC E-50) and (PVP) combination incorporating the drug Doxophylline and to execute the physicochemical and in vitro assessment. The motive was to provide the delivery of Doxophylline at a controlled rate across the intact skin to attain a therapeutically effective drug level for a longer time span from transdermal matrix patch.Method: Prefomulation studies and evaluation was done by using different parameter such as Partition coefficient, Physicochemical Compatibility of Drug and Polymer, Physical appearance, Thickness Measurement, Folding Endurance, Weight variation, Percentage moisture lost, Percentage moisture uptake, Drug content Determination.Result: The results shows that patches of Doxophylline obtained by the solvent evaporation method had acceptable physicochemical characteristics and satisfactory percentage drug release.Conclusion: The main conclusion of my work was formulating the Doxophylline transdermal system was to prolong the drug release time, reduce the frequency of administration and to improve patient compliance. Six formulations were prepared using two polymers in different ratios along with plasticizers and penetration enhancer.Keywords: Matrix transdermal patch, Doxofylline, Hydroxy propyl methyl cellulose E-50, Poly vinyl pyrrolidone, Dimethyl sulfoxide, Polyethyleneglycol 400

BENEFICIAL EFFECT OF VITAMIN D ON HIGH-FAT DIET-INDUCED OBESITY IN WISTAR RATS

ABSTRACTObjectives: The aim of the present study was to investigate the antiobesity effects of vitamin D (VD) on high-fat diet (HFD)-induced obesity in Wistarrats.Methods: In the present study, male Wistar rats were selected after 4 weeks feeding of HFD and then treated with different doses of VD(2.5-10 mcg/kg/day, p.o.o.d.) for 6 weeks along with HFD. Orlistat (30 mg/kg/day, p.o.o.d.), which is a lipase inhibitor a standard drug for obesitywas used as a standard control in the present study. The effects of these treatments on body weight parameters, feed intake (Kcal), weight and size offat pads, levels of serum glucose, triglycerides (TGs), total cholesterol (TC), high-density lipoproteins (HDL), and low-density lipoprotein (LDL) wereanalyzed.Results: Treatment with VD (2.5-10 mcg/kg/day, p.o.o.d.) produced significant dose-dependent decrease (p<0.05) in body weight parameters, feedintake (Kcal), weight and size of fat pads, levels of serum glucose, TGs, TC, and LDL as compared to HFD group. Moreover, the level of serum HDLs wasincreased as compared to HFD group.Conclusions: VD treatment ameliorated established obesity and associated biochemical consequences. The results suggest that administration of VDcan inhibit the development of obesity and associated metabolic consequences in HFD-induced obesity.Keywords: Obesity, Vitamin D, High-fat diet

VARIOUS BIOLOGICAL ACTIVITIES OF COUMARIN AND OXADIAZOLE DERIVATIVES

In this review article data is collected regarding the various derivatives of coumarin and oxadiazole as both these have wide range of biological activities and they can be further modified to synthesize more effective and potent drugs. Coumarin class of organic compounds consists of 1,2-benzopyrone ring system as a basic parent scaffold. These benzopyrones are subdivided into alpha-benzopyrones and gamma benzopyrones; with coumarin class of compounds belonging to alpha-benzopyrones. Since the last few years, coumarins were synthesized in many of their derivative forms. Their pharmacological, therapeutic and biochemical properties depend upon their pattern of substitution. Coumarins exhibit a wide range of pharmacological activities, which includes anti-diabetic, anti-viral, anti-microbial, anticancer, anti-oxidant, anti-parasitic, anti-helminthic, anti-proliferative, anti-convulsant, anti-inflammatory and antihypertensive activities. 1,3,4-Oxadiazole is a heterocyclic compound containing an oxygen atom and two nitrogen atoms in a five-membered ring. It is derived from furan by substitution of two methylene groups (=CH) with two pyridine type nitrogens (-N=). There are three known isomers: 1,2,4-oxadiazole, 1,2,3-oxadiazole and 1,2,5- oxadiazole. Oxadiazole moiety shows antimicrobial, anticancer and anti-inflammatory activity and suitably substituted 1,3,4-oxadiazole having biological activities like antimicrobial, anticancer and other biological activities

NANOSUSPENSION: AN OVERVIEW

Nanotechnology has emerged as a tremendous field in the medicine. Nano refers to particles size range of 1-1000nm. Nanosuspensions are part of nanotechnology. Nanosuspensions contain submicron colloidal dispersion of pharmaceutical active ingredient particles in a liquid phase stabilized by surfactants. Nanosuspension technology is a unique andeconomical approach to overcome poor bioavailability that is related with the delivery of hydrophobic drugs, including those that are poorly soluble in aqueous media. Nanosuspensions are important carriers to develop novel drug formulations. Few techniques such as precipitation methods, milling methods and homogenization methods are developed to produce nanosuspension (NS) and have been successfully employed in large-scale production. They are administered by Parenteral, per oral, ocular and pulmonary routes. Now their application also extended to site specific delivery. Nanosuspensions are prepared by using wet mill, high pressure homogenizer, emulsionâ€solvent evaporation, melt emulsification method and super critical fluid techniques. Nanosuspension technology can be used to improve the stability as well as bioavailability of poorly soluble drug. Nanosuspensions are also use in various dosage forms, including specialized drug delivery system such as mucoadhesive hydrogel. The unique features of nanosuspensions have enabled their use in various dosage forms, including specialized delivery systems such as mucoadhesive hydrogels. Rapid strides have been made in the delivery of nanosuspensions by parenteral, per-oral, ocular and pulmonary routes. Currently, efforts are being directed to extending their applications in site-specific drug delivery

Erratum: Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Interpretation: By quantifying levels and trends in exposures to risk factors and the resulting disease burden, this assessment offers insight into where past policy and programme efforts might have been successful and highlights current priorities for public health action. Decreases in behavioural, environmental, and occupational risks have largely offset the effects of population growth and ageing, in relation to trends in absolute burden. Conversely, the combination of increasing metabolic risks and population ageing will probably continue to drive the increasing trends in non-communicable diseases at the global level, which presents both a public health challenge and opportunity. We see considerable spatiotemporal heterogeneity in levels of risk exposure and risk-attributable burden. Although levels of development underlie some of this heterogeneity, O/E ratios show risks for which countries are overperforming or underperforming relative to their level of development. As such, these ratios provide a benchmarking tool to help to focus local decision making. Our findings reinforce the importance of both risk exposure monitoring and epidemiological research to assess causal connections between risks and health outcomes, and they highlight the usefulness of the GBD study in synthesising data to draw comprehensive and robust conclusions that help to inform good policy and strategic health planning

Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: A systematic analysis from the Global Burden of Disease Study 2016

Background: A key component of achieving universal health coverage is ensuring that all populations have access to quality health care. Examining where gains have occurred or progress has faltered across and within countries is crucial to guiding decisions and strategies for future improvement. We used the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) to assess personal health-care access and quality with the Healthcare Access and Quality (HAQ) Index for 195 countries and territories, as well as subnational locations in seven countries, from 1990 to 2016. Methods Drawing from established methods and updated estimates from GBD 2016, we used 32 causes from which death should not occur in the presence of effective care to approximate personal health-care access and quality by location and over time. To better isolate potential effects of personal health-care access and quality from underlying risk factor patterns, we risk-standardised cause-specific deaths due to non-cancers by location-year, replacing the local joint exposure of environmental and behavioural risks with the global level of exposure. Supported by the expansion of cancer registry data in GBD 2016, we used mortality-to-incidence ratios for cancers instead of risk-standardised death rates to provide a stronger signal of the effects of personal health care and access on cancer survival. We transformed each cause to a scale of 0-100, with 0 as the first percentile (worst) observed between 1990 and 2016, and 100 as the 99th percentile (best); we set these thresholds at the country level, and then applied them to subnational locations. We applied a principal components analysis to construct the HAQ Index using all scaled cause values, providing an overall score of 0-100 of personal health-care access and quality by location over time. We then compared HAQ Index levels and trends by quintiles on the Socio-demographic Index (SDI), a summary measure of overall development. As derived from the broader GBD study and other data sources, we examined relationships between national HAQ Index scores and potential correlates of performance, such as total health spending per capita. Findings In 2016, HAQ Index performance spanned from a high of 97\ub71 (95% UI 95\ub78-98\ub71) in Iceland, followed by 96\ub76 (94\ub79-97\ub79) in Norway and 96\ub71 (94\ub75-97\ub73) in the Netherlands, to values as low as 18\ub76 (13\ub71-24\ub74) in the Central African Republic, 19\ub70 (14\ub73-23\ub77) in Somalia, and 23\ub74 (20\ub72-26\ub78) in Guinea-Bissau. The pace of progress achieved between 1990 and 2016 varied, with markedly faster improvements occurring between 2000 and 2016 for many countries in sub-Saharan Africa and southeast Asia, whereas several countries in Latin America and elsewhere saw progress stagnate after experiencing considerable advances in the HAQ Index between 1990 and 2000. Striking subnational disparities emerged in personal health-care access and quality, with China and India having particularly large gaps between locations with the highest and lowest scores in 2016. In China, performance ranged from 91\ub75 (89\ub71-93\ub76) in Beijing to 48\ub70 (43\ub74-53\ub72) in Tibet (a 43\ub75-point difference), while India saw a 30\ub78-point disparity, from 64\ub78 (59\ub76-68\ub78) in Goa to 34\ub70 (30\ub73-38\ub71) in Assam. Japan recorded the smallest range in subnational HAQ performance in 2016 (a 4\ub78-point difference), whereas differences between subnational locations with the highest and lowest HAQ Index values were more than two times as high for the USA and three times as high for England. State-level gaps in the HAQ Index in Mexico somewhat narrowed from 1990 to 2016 (from a 20\ub79-point to 17\ub70-point difference), whereas in Brazil, disparities slightly increased across states during this time (a 17\ub72-point to 20\ub74-point difference). Performance on the HAQ Index showed strong linkages to overall development, with high and high-middle SDI countries generally having higher scores and faster gains for non-communicable diseases. Nonetheless, countries across the development spectrum saw substantial gains in some key health service areas from 2000 to 2016, most notably vaccine-preventable diseases. Overall, national performance on the HAQ Index was positively associated with higher levels of total health spending per capita, as well as health systems inputs, but these relationships were quite heterogeneous, particularly among low-to-middle SDI countries. Interpretation GBD 2016 provides a more detailed understanding of past success and current challenges in improving personal health-care access and quality worldwide. Despite substantial gains since 2000, many low-SDI and middle- SDI countries face considerable challenges unless heightened policy action and investments focus on advancing access to and quality of health care across key health services, especially non-communicable diseases. Stagnating or minimal improvements experienced by several low-middle to high-middle SDI countries could reflect the complexities of re-orienting both primary and secondary health-care services beyond the more limited foci of the Millennium Development Goals. Alongside initiatives to strengthen public health programmes, the pursuit of universal health coverage hinges upon improving both access and quality worldwide, and thus requires adopting a more comprehensive view-and subsequent provision-of quality health care for all populations

Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017

Background: Population estimates underpin demographic and epidemiological research and are used to track progress on numerous international indicators of health and development. To date, internationally available estimates of population and fertility, although useful, have not been produced with transparent and replicable methods and do not use standardised estimates of mortality. We present single-calendar year and single-year of age estimates of fertility and population by sex with standardised and replicable methods. Methods: We estimated population in 195 locations by single year of age and single calendar year from 1950 to 2017 with standardised and replicable methods. We based the estimates on the demographic balancing equation, with inputs of fertility, mortality, population, and migration data. Fertility data came from 7817 location-years of vital registration data, 429 surveys reporting complete birth histories, and 977 surveys and censuses reporting summary birth histories. We estimated age-specific fertility rates (ASFRs; the annual number of livebirths to women of a specified age group per 1000 women in that age group) by use of spatiotemporal Gaussian process regression and used the ASFRs to estimate total fertility rates (TFRs; the average number of children a woman would bear if she survived through the end of the reproductive age span [age 10–54 years] and experienced at each age a particular set of ASFRs observed in the year of interest). Because of sparse data, fertility at ages 10–14 years and 50–54 years was estimated from data on fertility in women aged 15–19 years and 45–49 years, through use of linear regression. Age-specific mortality data came from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 estimates. Data on population came from 1257 censuses and 761 population registry location-years and were adjusted for underenumeration and age misreporting with standard demographic methods. Migration was estimated with the GBD Bayesian demographic balancing model, after incorporating information about refugee migration into the model prior. Final population estimates used the cohort-component method of population projection, with inputs of fertility, mortality, and migration data. Population uncertainty was estimated by use of out-of-sample predictive validity testing. With these data, we estimated the trends in population by age and sex and in fertility by age between 1950 and 2017 in 195 countries and territories. Findings: From 1950 to 2017, TFRs decreased by 49·4% (95% uncertainty interval [UI] 46·4–52·0). The TFR decreased from 4·7 livebirths (4·5–4·9) to 2·4 livebirths (2·2–2·5), and the ASFR of mothers aged 10–19 years decreased from 37 livebirths (34–40) to 22 livebirths (19–24) per 1000 women. Despite reductions in the TFR, the global population has been increasing by an average of 83·8 million people per year since 1985. The global population increased by 197·2% (193·3–200·8) since 1950, from 2·6 billion (2·5–2·6) to 7·6 billion (7·4–7·9) people in 2017; much of this increase was in the proportion of the global population in south Asia and sub-Saharan Africa. The global annual rate of population growth increased between 1950 and 1964, when it peaked at 2·0%; this rate then remained nearly constant until 1970 and then decreased to 1·1% in 2017. Population growth rates in the southeast Asia, east Asia, and Oceania GBD super-region decreased from 2·5% in 1963 to 0·7% in 2017, whereas in sub-Saharan Africa, population growth rates were almost at the highest reported levels ever in 2017, when they were at 2·7%. The global average age increased from 26·6 years in 1950 to 32·1 years in 2017, and the proportion of the population that is of working age (age 15–64 years) increased from 59·9% to 65·3%. At the national level, the TFR decreased in all countries and territories between 1950 and 2017; in 2017, TFRs ranged from a low of 1·0 livebirths (95% UI 0·9–1·2) in Cyprus to a high of 7·1 livebirths (6·8–7·4) in Niger. The TFR under age 25 years (TFU25; number of livebirths expected by age 25 years for a hypothetical woman who survived the age group and was exposed to current ASFRs) in 2017 ranged from 0·08 livebirths (0·07–0·09) in South Korea to 2·4 livebirths (2·2–2·6) in Niger, and the TFR over age 30 years (TFO30; number of livebirths expected for a hypothetical woman ageing from 30 to 54 years who survived the age group and was exposed to current ASFRs) ranged from a low of 0·3 livebirths (0·3–0·4) in Puerto Rico to a high of 3·1 livebirths (3·0–3·2) in Niger. TFO30 was higher than TFU25 in 145 countries and territories in 2017. 33 countries had a negative population growth rate from 2010 to 2017, most of which were located in central, eastern, and western Europe, whereas population growth rates of more than 2·0% were seen in 33 of 46 countries in sub-Saharan Africa. In 2017, less than 65% of the national population was of working age in 12 of 34 high-income countries, and less than 50% of the national population was of working age in Mali, Chad, and Niger. Interpretation: Population trends create demographic dividends and headwinds (ie, economic benefits and detriments) that affect national economies and determine national planning needs. Although TFRs are decreasing, the global population continues to grow as mortality declines, with diverse patterns at the national level and across age groups. To our knowledge, this is the first study to provide transparent and replicable estimates of population and fertility, which can be used to inform decision making and to monitor progress

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

The Global Burden of Diseases, Injuries and Risk Factors 2017 includes a comprehensive assessment of incidence, prevalence, and years lived with disability (YLDs) for 354 causes in 195 countries and territories from 1990 to 2017. Previous GBD studies have shown how the decline of mortality rates from 1990 to 2016 has led to an increase in life expectancy, an ageing global population, and an expansion of the non-fatal burden of disease and injury. These studies have also shown how a substantial portion of the world's population experiences non-fatal health loss with considerable heterogeneity among different causes, locations, ages, and sexes. Ongoing objectives of the GBD study include increasing the level of estimation detail, improving analytical strategies, and increasing the amount of high-quality data. METHODS: We estimated incidence and prevalence for 354 diseases and injuries and 3484 sequelae. We used an updated and extensive body of literature studies, survey data, surveillance data, inpatient admission records, outpatient visit records, and health insurance claims, and additionally used results from cause of death models to inform estimates using a total of 68 781 data sources. Newly available clinical data from India, Iran, Japan, Jordan, Nepal, China, Brazil, Norway, and Italy were incorporated, as well as updated claims data from the USA and new claims data from Taiwan (province of China) and Singapore. We used DisMod-MR 2.1, a Bayesian meta-regression tool, as the main method of estimation, ensuring consistency between rates of incidence, prevalence, remission, and cause of death for each condition. YLDs were estimated as the product of a prevalence estimate and a disability weight for health states of each mutually exclusive sequela, adjusted for comorbidity. We updated the Socio-demographic Index (SDI), a summary development indicator of income per capita, years of schooling, and total fertility rate. Additionally, we calculated differences between male and female YLDs to identify divergent trends across sexes. GBD 2017 complies with the Guidelines for Accurate and Transparent Health Estimates Reporting